Connecticut Attorney General Secures Deal to Block Bootleg GLP-1 Weight Loss Drugs from ‘Made-in-China’
The surge in demand for GLP-1 weight loss medications has created a dangerous secondary market of unregulated, “bootleg” alternatives. In a significant move to protect public health, Connecticut Attorney General William Tong has announced a settlement with the international trade platform Made-in-China, requiring the company to cease all sales of unlawful “research grade” GLP-1s into the United States.
This agreement follows a targeted investigation into the platform’s role in distributing potent medications to consumers without prescriptions or medical supervision. For patients seeking weight loss solutions, this crackdown highlights a critical warning: not all medications marketed as “generics” or “research grade” are safe for human use.
The Settlement: Holding International Platforms Accountable
The investigation into Made-in-China began in May 2025, after it was discovered that the platform was facilitating the sale of bootleg GLP-1 weight loss drugs directly to Connecticut consumers. These transactions bypassed essential medical oversight, leaving users vulnerable to severe health risks.
Under the terms of the settlement agreement with the Office of the Attorney General, Made-in-China must implement the following measures:
- Prohibition of Sales: Manufacturers are strictly prohibited from using the platform to advertise or sell GLP-1s to customers located in the United States.
- Active Monitoring: The company is required to deploy a monitoring system specifically designed to detect and remove prohibited GLP-1 listings.
- Rapid Removal: Any identified GLP-1 listings must be removed from the platform within five days.
The Danger of “Research Grade” GLP-1s
A common tactic used by illicit sellers is labeling their products as “research grade.” In the medical community, this is a red flag. “Research grade” chemicals are intended for laboratory use and are not FDA approved for human use.
When consumers inject these substances, they are taking an enormous risk. According to the Attorney General’s office, studies have shown that bootleg GLP-1s can contain:
- Impurities: Unidentified chemical contaminants that can cause adverse reactions.
- Bacterial Contamination: A lack of sterile manufacturing processes can lead to serious infections.
- Inconsistent Dosages: Varying quantities of active ingredients can result in medication overdoses, which can be life-threatening.
How Consumers Are Deceived
Illicit sellers often use deceptive marketing to lure in people who cannot afford or obtain a prescription for brand-name medications. These sellers may falsely claim that their products are FDA-approved or are simply “generic” versions of well-known medications, including:
- Ozempic®
- Wegovy®
- Mounjaro®
- Zepbound®
It is important to understand that a legitimate generic medication is approved by the FDA and dispensed by a licensed pharmacy. Any “generic” sold on an international trade platform without a prescription is, by definition, bootleg and dangerous.
Key Takeaways for Patient Safety
- Avoid “Research Grade”: Never purchase any medication labeled “for research purposes only” or “not for human use.”
- Prescription Only: GLP-1 medications require a prescription and a physician’s oversight to manage dosing and monitor side effects.
- Verify Your Pharmacy: Only purchase medications from licensed, reputable pharmacies. Avoid third-party international trade sites.
- Beware of “Too Good to be True” Prices: Extreme discounts on brand-name weight loss drugs are often a sign of counterfeit products.
Looking Ahead
The settlement with Made-in-China is part of a broader effort to dismantle the supply chains of counterfeit pharmaceuticals. As the popularity of GLP-1 agonists continues to grow, regulatory bodies and health officials are increasing their vigilance. Consumers are urged to prioritize their safety over convenience or cost by consulting with a licensed healthcare provider for all weight management treatments.